🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Malignant Solid Tumors

    phase 1 small molecule completed

    3 trials

  2. Neratinib 160 mg

    PUMA BIOTECHNOLOGY, INC.

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  3. Niraparib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  4. OKI-179

    OnKure Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  5. OKI-219

    OnKure Therapeutics

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  6. OMP-131R10

    Mereo BioPharma Group plc

    Advanced Relapsed Tumors

    phase 1 small molecule completed

    1 trial

  7. OMP-305B83

    Mereo BioPharma Group plc

    Advanced Solid Tumor Malignancies

    phase 1 small molecule completed

    1 trial

  8. OMP-313M32

    Mereo BioPharma Group plc

    Locally Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  9. OMP-336B11

    Mereo BioPharma Group plc

    Locally Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  10. OMTX705-006 Phase 1b

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  11. OP-3136

    Olema Pharmaceuticals

    Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

    phase 1 small molecule active

    1 trial

  12. Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  13. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  14. PLN-101095

    PLIANT THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

  15. PRT543

    Prelude Therapeutics Inc

    Relapsed/Refractory Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  16. PRT7732

    Prelude Therapeutics Inc

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  17. PRT811

    Prelude Therapeutics Inc

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  18. PTC299

    PTC THERAPEUTICS, INC.

    Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  19. Palbociclib + Taselisib / Pictilisib

    United Therapeutics Europe Ltd

    Advanced Solid Tumours

    phase 1 small molecule completed

    1 trial

  20. Panobinostat (LBH589), Carboplatin and Paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  21. Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

    Istituto Gentili S.r.l.

    Mesothelioma

    phase 1 other active

    1 trial

  22. Pevonedistat

    Takeda

    Advanced Solid Tumors, Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  23. Pevonedistat

    Takeda

    Advanced Solid Neoplasm

    phase 1 small molecule completed

    2 trials

  24. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources